Summary of Research: HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

Detalles Bibliográficos
Publicado en:Targeted Oncology pp. 1 - 5
Autores principales: Dieras, Veronique, Curigliano, Giuseppe, Martin, Miguel, Lerebours, Florence, Tsurutani, Junji, Savard, Marie-France, Jerzak, Katarzyna J., Hu, Xichun, O’Sullivan, Ciara C., Tokunaga, Eriko, Okines, Alicia, Huang, Chiun-Sheng, Jacot, William, Sohn, Joohyuk, Cronemberger Silva, Eduardo, Mueller, Volkmar, Yang, Shan, Granata, Giovanna, Shen, Qi, Hamilton, Erika
Formato: Journal Article
Publicado: Springer Nature Sep2026
Acceso en línea:Ver este registro en EBSCOhost